MMWR News Synopsis for March 1, 2019

Use of Electronic Vapor Products Before, During, and After Pregnancy Among Women with a Recent Live Birth — Oklahoma and Texas, 2015

CDC Media Relations
404-639-3286

Although electronic vapor products (EVPs) typically contain nicotine, 1 in 15 women who recently gave birth in Oklahoma and Texas reported using EVPs. During the last three months of pregnancy, 1.4 percent of these women used EVPs. Among women who recently gave birth in Oklahoma and Texas, 7 percent reported using EVPs at some point before, during, or after pregnancy. EVPs typically contain nicotine, which can cause harm to the developing baby during pregnancy. Despite this risk, 2015 Pregnancy Risk Assessment Monitoring System data from Oklahoma and Texas show that EVP use occurs during pregnancy, particularly for recent cigarette smokers. These findings show the importance of messaging that EVPs are not safe to use during pregnancy. Health care providers can help women understand the impact of nicotine on fetal and infant health outcomes, and offer counseling and proven cessation treatment to prevent use of all tobacco products, including EVPs.

Progress toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus — Western Pacific Region, 2005–2017

CDC Media Relations
404-639-3286

Hepatitis B vaccination significantly reduced hepatitis B infections among children in the Western Pacific Region, from 8 percent (considered a high endemicity rate) to less than 1 percent (considered a low endemicity rate). Hepatitis B (HepB), a vaccine preventable disease, is a major cause of liver cancer. After all countries/areas in the Western Pacific Region (WPR) introduced the HepB vaccine into childhood immunization schedules, childhood infections dropped from a high of more than 8 percent in 1990 to less than 1 percent by 2017. These remarkable immunization achievements prevented more than 37 million chronic infections and 7 million HepB-related deaths. Further HepB control includes improving HepB birth-dose coverage through increased health facility births, antenatal training, and outside-the-cold-chain use. In addition to maintaining high vaccine coverage, additional interventions like routine antenatal testing, administration of hepatitis B immunoglobulin to exposed newborns, and antiviral treatment of mothers would be needed to achieve elimination of mother-to-child transmission of HepB by 2030.

Notes from the Field:

QuickStats:

###

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICESExternal

CDC works 24/7 protecting America’s health, safety, and security. Whether diseases start at home or abroad, are curable or preventable, chronic or acute, stem from human error or deliberate attack, CDC is committed to respond to America’s most pressing health challenges.

Page last reviewed: March 1, 2018